Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Pediatr Transplant ; 20(5): 619-26, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27090360

RESUMEN

Activation of the RAS has a crucial role in the progression of ischemia/reperfusion-associated CAD. The regulation of RAS differs in the two genders. However, the extent of gender differences and locations of renin production have not been revealed yet. We investigated in vivo the local renin production in the two genders during ischemia/reperfusion injury. In male and female Wistar rats, renal ischemia was induced followed by a reperfusion period of two, eight, 16, 24, or 48 h. We applied flow cytometry to measure renin content and multiphoton imaging to visualize renin granules and changes of peritubular diameters in vivo during ischemia/reperfusion. Renin content decreased in CD in the first eight h of reperfusion; however, after 16 h, its amount increased. In males, the production of renin was more pronounced, and the duration of vasoconstriction was longer with a subsequent phase of vessel hyperdilation compared to females. Renal ischemia/reperfusion injury induces renin response not only in the JGA, but also in the CD segment. Renin production is more explicit in males than in females which, via increased angiotensin II production, might explain the different dynamism of renal vessel regulation between the two genders.


Asunto(s)
Capilares/fisiopatología , Trasplante de Riñón , Riñón/fisiopatología , Sistema Renina-Angiotensina/fisiología , Renina/metabolismo , Daño por Reperfusión/fisiopatología , Animales , Biomarcadores/metabolismo , Femenino , Citometría de Flujo , Riñón/irrigación sanguínea , Riñón/metabolismo , Masculino , Microscopía Fluorescente , Ratas , Ratas Wistar , Daño por Reperfusión/metabolismo , Factores Sexuales , Vasoconstricción , Vasodilatación
2.
Transplantation ; 100(2): 325-333, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26502369

RESUMEN

BACKGROUND: Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allograft rejection. Calcineurin inhibitors are known to be nephrotoxic. However, the precise mechanism of nephrotoxicity is not fully understood. In this study, we investigated the in vivo effects of CNIs on the local renal renin-angiotensin system in the collecting duct (CD). METHODS: Three-week-old mice were treated with either vehicle, CyA (2 mg/kg per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks. Serum creatinine was measured. Renin and vascular endothelial growth factor (VEGF) contents in CD were evaluated with flow cytometry and multiphoton microscopy. The diameter of vessels was assessed with multiphoton microscopy, and the amount of renal collagen was determined by real-time polymerase chain reaction and Masson staining. RESULTS: The elevated level of serum creatinine in CNI groups was abolished by Aliskiren. Flow cytometric analysis found elevated renin content in principal cells, which was prevented by Aliskiren. This result was further confirmed with multiphoton microscopy. The VEGF content in CD correlated with reduced capillary diameter and with the formation of fibrotic islands. CONCLUSIONS: Calcineurin inhibitors induce production of renin in the CD that may contribute to decreased renal blood flow. In turn, CD responds with increased VEGF production, resulting in disproportional vessel growth, further worsening the local hypoxia and striped fibrosis surrounding the CDs. Aliskiren, a direct renin inhibitor blocks these effects and improves CNI-induced nephropathy by decreasing renin production in the CDs. Our data suggest that Aliskiren may be used for the prevention of CNI nephrotoxicity.


Asunto(s)
Inhibidores de la Calcineurina , Ciclosporina , Inmunosupresores , Enfermedades Renales/inducido químicamente , Túbulos Renales Colectores/efectos de los fármacos , Sistema Renina-Angiotensina/efectos de los fármacos , Renina/metabolismo , Tacrolimus , Factor A de Crecimiento Endotelial Vascular/metabolismo , Amidas/farmacología , Animales , Biomarcadores/sangre , Capilares/metabolismo , Capilares/patología , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Creatinina/sangre , Citoprotección , Modelos Animales de Enfermedad , Fibrosis , Citometría de Flujo , Fumaratos/farmacología , Enfermedades Renales/genética , Enfermedades Renales/metabolismo , Enfermedades Renales/patología , Enfermedades Renales/prevención & control , Túbulos Renales Colectores/irrigación sanguínea , Túbulos Renales Colectores/metabolismo , Túbulos Renales Colectores/patología , Masculino , Ratones Endogámicos C57BL , Microscopía de Fluorescencia por Excitación Multifotónica , Reacción en Cadena en Tiempo Real de la Polimerasa , Circulación Renal , Renina/antagonistas & inhibidores , Factores de Tiempo , Regulación hacia Arriba
3.
J Am Soc Nephrol ; 26(11): 2731-40, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25788535

RESUMEN

Intrarenal changes in cytoplasmic calcium levels have a key role in determining pathologic and pharmacologic responses in major kidney diseases. However, cell-specific delivery of calcium-sensitive probes in vivo remains problematic. We generated a transgenic rat stably expressing the green fluorescent protein-calmodulin-based genetically encoded calcium indicator (GCaMP2) predominantly in the kidney proximal tubules. The transposon-based method used allowed the generation of homozygous transgenic rats containing one copy of the transgene per allele with a defined insertion pattern, without genetic or phenotypic alterations. We applied in vitro confocal and in vivo two-photon microscopy to examine basal calcium levels and ligand- and drug-induced alterations in these levels in proximal tubular epithelial cells. Notably, renal ischemia induced a transient increase in cellular calcium, and reperfusion resulted in a secondary calcium load, which was significantly decreased by systemic administration of specific blockers of the angiotensin receptor and the Na-Ca exchanger. The parallel examination of in vivo cellular calcium dynamics and renal circulation by fluorescent probes opens new possibilities for physiologic and pharmacologic investigations.


Asunto(s)
Calcio/metabolismo , Túbulos Renales Proximales/metabolismo , Microscopía Confocal , Transgenes , Animales , Animales Modificados Genéticamente , Citoplasma/metabolismo , Femenino , Proteínas Fluorescentes Verdes/metabolismo , Homocigoto , Hipoxia/patología , Isquemia/patología , Riñón/metabolismo , Riñón/patología , Corteza Renal/metabolismo , Enfermedades Renales/patología , Túbulos Renales/metabolismo , Túbulos Renales Proximales/patología , Ligandos , Ratas , Daño por Reperfusión , Intercambiador de Sodio-Calcio/metabolismo
4.
Pediatr Nephrol ; 28(10): 2061-4, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23800802

RESUMEN

BACKGROUND: The pathogenicity of the NPHS2 homozygous p.R229Q variant in steroid-resistant nephrotic syndrome (SRNS) is doubtful. While it has been reported in unaffected controls, it is enriched in patients with SRNS, suggesting pathogenicity. CASE-DIAGNOSIS/TREATMENT: A family with three members homozygous for the NPHS2 p.R229Q variant is presented: a 37-year-old patient who was diagnosed with proteinuria at age 7 months, focal segmental glomerulosclerosis (FSGS) at age 20 years, and end-stage renal disease (ESRD) at age 33 years, his 59 year-old father and his 40 year-old brother, both unaffected with no proteinuria. The affected son also harbors a heterozygous de novo, truncating PAX2 mutation (c.76dupG, p.V26Gfs*28), which can explain his chronic renal failure but which is rarely associated with FSGS. CONCLUSIONS: This family provides further evidence that homozygous p.R229Q in itself may not cause FSGS. Nevertheless, the rare association of FSGS to a PAX2 mutation may reflect the modifier effect of p.R229Q in the homozygous state. Such a modifier effect can also explain its enrichment in SRNS patients. Patients with homozygous p.R229Q should be screened for the causative mutation in a second gene.


Asunto(s)
Genes Modificadores , Variación Genética , Glomeruloesclerosis Focal y Segmentaria/genética , Homocigoto , Péptidos y Proteínas de Señalización Intracelular/genética , Proteínas de la Membrana/genética , Adulto , Análisis Mutacional de ADN , Progresión de la Enfermedad , Predisposición Genética a la Enfermedad , Glomeruloesclerosis Focal y Segmentaria/complicaciones , Glomeruloesclerosis Focal y Segmentaria/diagnóstico , Glomeruloesclerosis Focal y Segmentaria/terapia , Herencia , Humanos , Fallo Renal Crónico/genética , Laminina/genética , Masculino , Persona de Mediana Edad , Mutación , Factor de Transcripción PAX2/genética , Linaje , Fenotipo , Proteinuria/genética , Factores de Riesgo
5.
Orv Hetil ; 154(17): 643-9, 2013 Apr 28.
Artículo en Húngaro | MEDLINE | ID: mdl-23608311

RESUMEN

The renin-angiotensin system is one of the most important hormone systems in the body, and the regulations as well as the role in the juxtaglomerular apparatus are well known. The present review focuses on renin secretion in a recently described localization, the cortical collecting duct. The authors display it in parallel of the copying strategy of an adult and a developing kidney. Furthermore, based on different animal studies it highlights the local role of renin released from the collecting duct. In chronic angiotensin II-infused, 2-kidney, 1-clip hypertensive model as well as in diabetic rats the major source of (pro)renin is indeed the collecting duct. In this localization this hormone can reach both the systemic circulation and the interstitial renin-angiotensin system components including the newly described (pro)renin receptor, by which (pro)renin is able to locally activate pro-fibrotic intracellular signal pathways. Consequently, one can postulate that in the future renin may serve either as a new therapeutic target in nephropathy associated with both hypertension and diabetes or as an early diagnostic marker in chronic diseases leading to nephropathy.


Asunto(s)
Angiotensina II/metabolismo , Hipertensión/metabolismo , Túbulos Renales Colectores/metabolismo , Túbulos Renales Colectores/fisiopatología , Sistema Renina-Angiotensina , Renina/metabolismo , Animales , Presión Sanguínea , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/fisiopatología , Femenino , Feto/metabolismo , Feto/fisiopatología , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Aparato Yuxtaglomerular/metabolismo , Aparato Yuxtaglomerular/fisiopatología , Túbulos Renales Colectores/embriología , Embarazo , Complicaciones Cardiovasculares del Embarazo/metabolismo , Complicaciones Cardiovasculares del Embarazo/fisiopatología , Renina/biosíntesis , Sistema Renina-Angiotensina/fisiología
6.
Pediatr Nephrol ; 28(5): 751-7, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23242530

RESUMEN

BACKGROUND: The most frequently mutated gene of steroid-resistant nephrotic syndrome (SRNS) is NPHS2. Current guidelines propose the sequencing of all NPHS2 exons only in childhood-onset SRNS. METHODS: A cohort of 38 Hungarian patients with childhood-onset nephrotic-range proteinuria was screened for NPHS2 mutations. The frequency of the p.V290M mutation in late-onset SRNS was examined in the French and PodoNet cohorts. RESULTS: Of the 38 Hungarian patients screened, seven carried NPHS2 mutations on both alleles, of whom two-diagnosed with proteinuria through school screening programs at the age of 9.7 and 14 years, respectively-did not develop nephrotic syndrome in childhood. The first, an 18-year-old boy, homozygous for p.V290M, has never developed edema. The second, a 31-year-old woman-compound heterozygous for p.V290M and p.R138Q-was first detected with hypoalbuminemia (<30 g/l) and edema at the age of 24.3 and 27.5 years, respectively. Both patients currently have a normal glomerular filtration rate. The mutation p.V290M was carried by three of the 38 patients in the Hungarian cohort, by two of the 95 patients with late-onset SRNS in the PodoNet cohort and by none of the 83 patients in the French cohort. CONCLUSIONS: We propose that not only the p.R229Q variant, but also the p.V290M mutation should be screened in Central and Eastern European patients with late-onset SRNS.


Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/genética , Proteínas de la Membrana/genética , Mutación Missense , Síndrome Nefrótico/congénito , Adolescente , Adulto , Edad de Inicio , Niño , Preescolar , Análisis Mutacional de ADN , Europa (Continente)/epidemiología , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Pruebas Genéticas/métodos , Tasa de Filtración Glomerular , Haplotipos , Heterocigoto , Homocigoto , Humanos , Lactante , Riñón/fisiopatología , Masculino , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/epidemiología , Síndrome Nefrótico/genética , Síndrome Nefrótico/fisiopatología , Fenotipo , Proteinuria/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...